![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vascular Medicine Section, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA 02115
3To whom correspondence should be addressed. E-mail: mcreager{at}partners.org.
The vascular endothelium is a crucial regulator of vascular function and homeostasis. Nitric oxide (NO) is an important paracrine substance released by the endothelium to regulate vasomotor tone. Risk factors for atherosclerosis, as well as atherosclerosis per se, are associated with endothelial dysfunction and decreased bioavailablilty of NO. Indeed, endothelial dysfunction is integral to the pathogenesis of atherosclerosis and other cardiovascular diseases. Moreover, endothelial dysfunction relates to an increased risk of adverse cardiovascular outcomes. L-Arginine is an essential amino acid required by the constitutive enzyme, endothelial NO oxide synthase (eNOS), to produce NO. Administration of L-arginine improves endothelial function in animal models and in humans with hypercholesterolemia and with atherosclerosis. Clinical trials to date support potential clinical applications of L-arginine in the treatment of coronary artery disease and peripheral arterial disease, as well as in the prevention of in-stent restenosis. The mechanism of benefit of L-arginine on endothelial function is unclear, because intracellular concentrations of L-arginine far exceed that required by eNOS. One potential explanation of this "arginine paradox" is that L-arginine restores endothelial function in atherosclerotic patients, in whom there are elevated levels of asymmetric dimethylarginine, an endogenous inhibitor of eNOS. Given the promising findings of early studies of L-arginine as a potential therapy for cardiovascular disorders, large-scale clinical trials are warranted.
KEY WORDS: • endothelium • arginine • nitric oxide • cardiovascular disease
This article has been cited by other articles:
|
|
 |
|
  J. Magne, J. F. Huneau, D. Tsikas, S. Delemasure, L. Rochette, D. Tome, and F. Mariotti Rapeseed Protein in a High-Fat Mixed Meal Alleviates Postprandial Systemic and Vascular Oxidative Stress and Prevents Vascular Endothelial Dysfunction in Healthy Rats J. Nutr., September 1, 2009; 139(9): 1660 - 1666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ohashi, N. Ouchi, K. Sato, A. Higuchi, T.-o Ishikawa, H. R. Herschman, S. Kihara, and K. Walsh Adiponectin Promotes Revascularization of Ischemic Muscle through a Cyclooxygenase 2-Dependent Mechanism Mol. Cell. Biol., July 1, 2009; 29(13): 3487 - 3499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ros Nuts and novel biomarkers of cardiovascular disease Am. J. Clinical Nutrition, May 1, 2009; 89(5): 1649S - 1656S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Siekmeier, T. Grammer, and W. Marz Roles of Oxidants, Nitric Oxide, and Asymmetric Dimethylarginine in Endothelial Function Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2008; 13(4): 279 - 297. [Abstract] [PDF]
|
|
|
|
|
|
F. Mariotti, J. F. Huneau, I. Szezepanski, K. J. Petzke, Y. Aggoun, D. Tome, and D. Bonnet Meal Amino Acids with Varied Levels of Arginine do Not Affect Postprandial Vascular Endothelial Function in Healthy Young Men J. Nutr., June 1, 2007; 137(6): 1383 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Grimble Adverse Gastrointestinal Effects of Arginine and Related Amino Acids J. Nutr., June 1, 2007; 137(6): 1693S - 1701S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Ohta, T. Takagi, H. Sato, and L. J. Ignarro Low-dose L-arginine administration increases microperfusion of hindlimb muscle without affecting blood pressure in rats PNAS, January 23, 2007; 104(4): 1407 - 1411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Bode-Boger, F. Scalera, J. T. Kielstein, J. Martens-Lobenhoffer, G. Breithardt, M. Fobker, and H. Reinecke Symmetrical Dimethylarginine: A New Combined Parameter for Renal Function and Extent of Coronary Artery Disease J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1128 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Herman and S. Moncada Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis Eur. Heart J., October 1, 2005; 26(19): 1945 - 1955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M Morris JR Arginine metabolism in vascular biology and disease Vascular Medicine, July 1, 2005; 10(1_suppl): S83 - S87. [Abstract] [PDF]
|
|
|
|
|
|
S. M Morris Jr Arginine metabolism in vascular biology and disease Vascular Medicine, May 1, 2005; 10(2_suppl): S83 - S87. [Abstract] [PDF]
|
|
